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 Implication for health policy/practice/research/medical edu-
cation:
This article focuses on impact of IL28B polymorphisms on hep-
atitis C outcomes. This study is recommended to clinicians and 
researchers in the field of viral hepatitis.
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Hepatitis C infection is a major global public health 
problem (1). Treatment of hepatitis C with pegylated in-
terferon α plus Ribavirin as a standard of care (SoC) for 
the management of this disease, leads to eradication of 
the virus in less than 60% of patients (2). Different sus-
tained virological response (SVR) rates in different pop-
ulations is a challenging fact that has been observed by 
researchers and inspired them to search for the causes 
(3). In September 2009, Ge et al. (4) in a genome-wide as-
sociation study (GWAS) found the rs12979860 single nu-
cleotide polymorphism (Snp), which is located 3 kb up-
stream of the IL28B gene, to be the strongest host genetic 
predictor of SVR in hepatitis C genotype 1. They observed 
that rs12979860 CC patients, regardless of their ethnicity, 
reach SVR rates approximately twice that of rs12979860 
TT patients. In less than a 3 year time span, from the 
first report by Ge et al. till the present (December 2011), 
around 250 papers on the association of IL28B Snp with 
hepatitis  C  outcomes  have  been  indexed  in  Medline/
pubmed, which is a singular reflection of the high im-
portance this topic has for medical researchers. Also, Ge 
et al. found a different frequency of the IL28B rs12979860, 
with the highest favorable allele in Asians and the low-
est in Africans, which in part elucidates the high rate of 
SVR in Asians and the low rate of SVR in Africans. Later 
in 2009, two GWAS by Suppiah et al. (5) and Tanaka et al. 
(6) found rs8099917, another IL28B polymorphism which 
is located around 8 kb upstream of the IL28B gene, to be 
the strongest genetic determinant of SVR in hepatitis C 
virus (HCV) genotype 1 infected patients. Here we should 
note that: 
1) These two Snps, rs12979860 and rs8099917, are in par-
tial linkage disequilibrium (LD) in Caucasians (4, 7) and 
2) Although a few studies such as a meta-analysis by Li et 
al. (8) showed that rs12979860 can predict SVR better than 
rs8099917, further studies are needed to assess the exact 
role and impact of each of these two Snps on hepatitis C 
outcomes in different populations. Initially, most of the 
studies concentrated on the HCV genotype 1, which is the 
most frequent type in Western countries, and observed 
the same association between IL28B Snp and SVR that 
was found by Ge et al. on the other hand, the impact of 
IL28B polymorphisms on the outcome of HCV genotypes 
non-1 such as HCV genotype 4 (9, 10) and HCV genotype 2 
or 3 (7, 11-13) has been studied as well. Unlike the results of 
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in HCV genotype 1 infected patients, results of studies us-
ing HCV genotype 2 or 3 infected patients are not similar 
and some found no association between IL28B Snp and 
SVR to standard of care in HCV genotype 2 or 3 infected 
patients (7, 12), while some found such an association (11, 
13). SVR as a hepatitis C treatment outcome can be pre-
dicted by various baseline predictors such as HCV RnA 
levels, the dose and duration of therapy, body mass in-
dex, age, insulin resistance, gender, stage of fibrosis and 
co-infection with other hepatitis viruses or HIV (14). Also, 
we know that the viral kinetic which is assessed by the 
rapid virological response (RVR) can predict SVR stronger 
than baseline predictors that have been identified above. 
In 2009, after the discovery of IL28B Snp as the strongest 
host genetic determinant of SVR, we assumed that IL28B 
Snp could be an alternative to RVR, but according to our 
experience it seems that RVR is a reflection of all known 
and unknown predictors of treatment outcome and can-
not be replaced by IL28B Snp.
In 2011, the European Association for the Study of the 
Liver (EASL) and the American Association for the Study 
of Liver Diseases (AASLD) included IL28B testing in their 
guidelines (14, 15). Here we recommend that physicians 
consider IL28B genotyping in the sub-groups of patients 
with indications for IL28B testing according to eASL and/
or AASLD guidelines. Also, relapsers and non-responders 
with  favorable  pre-treatment  predictors  compel  us  to 
investigate  and  discover  new  predictors  that  can  ex-
plain treatment failure in such patients. Sporea et al. (16) 
studied the correlation of IL28B rs12979860 with SVR in 
Romanian patients with chronic hepatitis C treated with 
a SoC regimen and subsequently observed SVR rates ap-
proximately 30% higher in rs12979860 CC patients than 
in non-CC patients. We noticed that in their study, IL28B 
rs12979860 genotype distribution was not in the Hardy-
Weinberg equilibrium (HWe). Since the deviation from 
HWe  can  be  a  result  of  genotyping  error,  researchers 
should test the genotyping data for deviation from HWe 
and should consider it in their reports (17). Finally, we 
report that the finding of the correlation between IL28B 
Snp and hepatitis C outcomes, in part clarified the inter-
individual variation in treatment responses observed 
in the clinic. IL28B Snp as a pharmacogenetic marker of 
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